These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30821923)

  • 1. The impact of postreperfusion syndrome during liver transplantation using livers with significant macrosteatosis.
    Croome KP; Lee DD; Croome S; Chadha R; Livingston D; Abader P; Keaveny AP; Taner CB
    Am J Transplant; 2019 Sep; 19(9):2550-2559. PubMed ID: 30821923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Donor Allograft Microsteatosis Matter? Comparison of Outcomes in Liver Transplantation With a Propensity-Matched Cohort.
    Croome KP; Lee DD; Croome S; Nakhleh RE; Abader Sedki Senada P; Livingston D; Yataco M; Taner CB
    Liver Transpl; 2019 Oct; 25(10):1533-1540. PubMed ID: 31187923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative and long-term outcomes of utilizing donation after circulatory death liver grafts with macrosteatosis: A multicenter analysis.
    Croome KP; Mathur AK; Mao S; Aqel B; Piatt J; Senada P; Heimbach JK; Moss A; Rosen CB; Taner CB
    Am J Transplant; 2020 Sep; 20(9):2449-2456. PubMed ID: 32216008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential Protocol Biopsies Post-Liver Transplant From Donors With Moderate Macrosteatosis: What Happens to the Fat?
    Croome KP; Livingston D; Croome S; Keaveny AP; Taner CB; Nakhleh R
    Liver Transpl; 2021 Feb; 27(2):248-256. PubMed ID: 32779325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of steatotic donor livers on the prognosis of donors and recipients after pediatric living donor liver transplantation].
    Yang Y; Dong C; Sun C; Wang K; Zhang W; Zheng WP; Zhang FB; Qin H; Han C; Wang Z; Xu M; Gao W
    Zhonghua Wai Ke Za Zhi; 2022 Oct; 60(10):922-929. PubMed ID: 36207981
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatic macrosteatosis in the US pediatric deceased liver donor population.
    Purvis JW; Orandi BJ; Dhall D; McLeod C; Gutierrez Sanchez LH; Gray M; Frey K; Sheikh SS; Cannon RM; Terrault NA; Lewis CE; Locke JE
    Pediatr Transplant; 2022 Feb; 26(1):e14155. PubMed ID: 34590386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor Hepatic Steatosis Induce Exacerbated Ischemia-Reperfusion Injury Through Activation of Innate Immune Response Molecular Pathways.
    Gehrau RC; Mas VR; Dumur CI; Suh JL; Sharma AK; Cathro HP; Maluf DG
    Transplantation; 2015 Dec; 99(12):2523-33. PubMed ID: 26285018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative complications in liver transplantation using donation after cardiac death grafts: a propensity-matched study.
    Pan X; Apinyachon W; Xia W; Hong JC; Busuttil RW; Steadman RH; Xia VW
    Liver Transpl; 2014 Jul; 20(7):823-30. PubMed ID: 24711100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimizing Risks of Liver Transplantation With Steatotic Donor Livers by Preferred Recipient Matching.
    Jackson KR; Motter JD; Haugen CE; Long JJ; King B; Philosophe B; Massie AB; Cameron AM; Garonzik-Wang J; Segev DL
    Transplantation; 2020 Aug; 104(8):1604-1611. PubMed ID: 32732837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postreperfusion hyperkalemia in liver transplantation using donation after cardiac death grafts with pathological changes.
    Zhang WJ; Xia WL; Pan HY; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):487-492. PubMed ID: 27733317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asystolic donor warm ischemia time is associated with development of postreperfusion syndrome in donation after circulatory death liver transplant.
    Bekki Y; Rocha C; Myers B; Wang R; Smith N; Tabrizian P; DiNorcia J; Moon J; Arvelakis A; Facciuto ME; DeMaria S; Florman S
    Clin Transplant; 2024 May; 38(5):e15336. PubMed ID: 38762783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postreperfusion syndrome in liver transplantation: Outcomes, predictors, and application for recipient selection.
    Bekki Y; Myers B; Wang R; Smith N; Zerillo J; Rocha C; Tabrizian P; Moon J; Arvelakis A; Facciuto ME; DeMaria S; Florman S
    Clin Transplant; 2022 Apr; 36(4):e14587. PubMed ID: 34997798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrosteatotic Allografts and Obese Recipients Have Nearly Equal Negative Impact on Liver Transplant Survival.
    Northup PG; Intagliata NM; Davis JPE; Argo CK; Pelletier SJ
    Transplantation; 2020 Jun; 104(6):1193-1200. PubMed ID: 31577675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment.
    Spitzer AL; Lao OB; Dick AA; Bakthavatsalam R; Halldorson JB; Yeh MM; Upton MP; Reyes JD; Perkins JD
    Liver Transpl; 2010 Jul; 16(7):874-84. PubMed ID: 20583086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Postreperfusion Syndrome on Acute Kidney Injury in Living Donor Liver Transplantation: A Propensity Score Analysis.
    Jun IG; Kwon HM; Jung KW; Moon YJ; Shin WJ; Song JG; Hwang GS
    Anesth Analg; 2018 Aug; 127(2):369-378. PubMed ID: 29596092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderately Macrosteatotic Livers Have Acceptable Long-Term Outcomes but Higher Risk of Immediate Mortality.
    Alvikas J; Deeb AP; Jorgensen DR; Minervini MI; Demetris AJ; Lemon K; Chen X; Labiner H; Malik S; Hughes C; Humar A; Tevar A
    Transplant Proc; 2021 Jun; 53(5):1682-1689. PubMed ID: 33931249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual quality assessment of the liver graft by the transplanting surgeon predicts postreperfusion syndrome after liver transplantation: a retrospective cohort study.
    Kork F; Rimek A; Andert A; Becker NJ; Heidenhain C; Neumann UP; Kroy D; Roehl AB; Rossaint R; Hein M
    BMC Anesthesiol; 2018 Mar; 18(1):29. PubMed ID: 29523082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Utility of Extended Criteria Donor Livers in High Acuity Liver Transplant Recipients.
    Guorgui J; Ito T; Younan S; Agopian VG; Dinorcia J; Farmer DG; Busuttil RW; Kaldas FM
    Am Surg; 2021 Dec; 87(10):1684-1689. PubMed ID: 34130521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Rifaximin Therapy on Ischemia/Reperfusion Injury in Liver Transplantation: A Propensity Score-Matched Analysis.
    Ito T; Nakamura K; Kageyama S; Korayem IM; Hirao H; Kadono K; Aziz J; Younan S; DiNorcia J; Agopian VG; Yersiz H; Farmer DG; Busuttil RW; Kupiec-Weglinski JW; Kaldas FM
    Liver Transpl; 2019 Dec; 25(12):1778-1789. PubMed ID: 31509643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of liver transplantation with liver grafts from pediatric donors used in adult recipients.
    Croome KP; Lee DD; Burns JM; Saucedo-Crespo H; Perry DK; Nguyen JH; Taner CB;
    Liver Transpl; 2016 Aug; 22(8):1099-106. PubMed ID: 27145067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.